Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00009984 · ClinicalTrials.gov registry record · Phase 2
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00009984: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00009984 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00009984, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying thalidomide and fludarabine to see how well they work compared to thalidomide alone in treating patients with hematologic cancer that has not responded to previous treatment with fludarabine. Thalidomide may stop the growth of hematologic cancer by stopping blood flow to the cancer. Combining thalidomide with fludarabine may increase the effectiveness of chemotherapy by making cancer cells more sensitive to the drug. It is not yet known whether thalidomide is more effective with or without fludarabine for hematologic cancer.
Interventions
- DRUG fludarabine phosphate
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2002-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00009984
The ClinicalTrials.gov registry entry for NCT00009984 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fludarabine phosphate is the first listed.
NCT00009984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00009984 about?
NCT00009984 is a clinical study titled "Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer". This randomized phase II trial is studying thalidomide and fludarabine to see how well they work compared to thalidomide alone in treating patients with hematologic cancer that has not responded to previous treatment with fludarabine. Thalidomide may stop the growth of hematologic cancer by stopping...
What is the current status of trial NCT00009984?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2002-03.
What interventions are being tested in trial NCT00009984?
The interventions under investigation include: fludarabine phosphate (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00009984?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.